Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Abstract
-
Article
Monitoring breast carcinoma with CA 15-3 and CEA
-
Article
Monitoring ovarian carcinoma with CA 125, CA 19–9, CA 15–3 and CEA in serum, ascites and tumor tissue
-
Article
Disseminated tescicular cancer with bulky disease: Results of a phase-II study of the AIO with cisplatinum ultra high dose/VP16/bleomycin